Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a National High-tech Enterprise founded in 1998 and listed on the Shenzhen Stock Exchange in 2009. The company specializes in high-end chemical pharmaceuticals, biological medicines, and biomedical fields, focusing on innovative solutions in the therapeutic areas of cardiovascular, anti-diabetic, antineoplastic, and orthopedic treatments. Salubris is recognized for its commitment to quality and innovation, with a strong emphasis on research and development. The company operates a comprehensive product portfolio that includes both generic and original products, with a strategic focus on short-term, mid-term, and long-term development. Key products include TAIJIA, an antiplatelet aggregation medication, and XINLITAN, an antihypertensive medicine. Salubris has established a robust sales network covering secondary and tertiary hospitals nationwide, supported by a professional Evidence-based Medicine (EBM) promotion team. The company aims to enhance its product pipeline through independent innovation and collaborations, positioning itself as a leading international innovative pharmaceutical enterprise.

R&D is the sustainable driven force of the company. The over 600 R&D team located in Shenzhen, Chengdu and Maryland State, America.The investment for R&D was 0.439 billion yuan(RMB), occupying 10.57% of the revenue.Meanwhile, Salubris is in long-term collaboration with the R&D institutes and building research platforms together,achieving the transformation of domestic and international scientific and technological achievements. Salubris products combine generic and original products, establishing short-term, mid-term and long-term product portfolio strategy. The R&D projects include many innovative medicines. Chemical pharmaceuticals are included in short-term and mid-term strategy, which will be in the stage of rich the product line rapidly in the next 2 to 3 years. The innovative biological medicines are the middle- and long-term products planning, laying a foundation for the company to become an excellent biological enterprise. Salubris is patient-oriented and based on high quality products in the market. The products’ internal control standard is higher than that of the National Pharmacopoeia. As the first domestic enterprise achieved EU GMP certification on both API and Formulation of Clopidogrel, the product quality has been acknowledged worldwide. In the EBM (Evidence-base Medicine) promotion field, the professional promotion team has been highly acknowledged in areas of expertise. The distribution channels are across national Secondary and Tertiary Hospitals, which also extended to primary hospitals. In addition, Salubris has set up a marketing team in retail outlet, forming a vertical and full-covering sales network. In addition, Salubris established an academic platform with outstanding specialists and hospitals to conduct intensive evidence-based research. With the successful promotion of new products, Salubris’ profitability will be gradually improved.